NO20080113L - Kombinasjonsterapi for behandling av immunoinflammatorisk forstyrrelse - Google Patents

Kombinasjonsterapi for behandling av immunoinflammatorisk forstyrrelse

Info

Publication number
NO20080113L
NO20080113L NO20080113A NO20080113A NO20080113L NO 20080113 L NO20080113 L NO 20080113L NO 20080113 A NO20080113 A NO 20080113A NO 20080113 A NO20080113 A NO 20080113A NO 20080113 L NO20080113 L NO 20080113L
Authority
NO
Norway
Prior art keywords
treatment
agent
combination therapy
nsidi
metabolite
Prior art date
Application number
NO20080113A
Other languages
English (en)
Inventor
Edward Roydon Jost-Price
Bradley B Brasher
Noah Sachs
Palaniyandi Manivasakam
Daniel Grau
Benjamin A Auspitz
Todd W Chappell
Michael G Frank
Seth Lederman
Brendan Smith
Original Assignee
Combinatorx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37570780&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20080113(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Combinatorx Inc filed Critical Combinatorx Inc
Publication of NO20080113L publication Critical patent/NO20080113L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Oppfinnelsen angår en fremgangsmåte for behandling av en pasient diagnostisert med eller med risiko for å utvikle, en immuninflammatorisk forstyrrelse ved administrering av et ikke-steroid immunophilin-avhengig immunosuppressivt middel (NsIDI) og en gruppe A-enhancer (f.eks. antifungalt middel, giktmiddel, anti-infektive agens, antiprotozomiddel, antiviralt middel, fuktighetsbevarende middel, solfaktor, vitamin D-forbindelse, mikrotubulin-inhibitor eller sinksalt) eller analog eller metabolitt derav til pasienten. Oppfinnelsen angår også en farmasøytisk sammensetning inneholdende en NsIDI og Gruppe A-enhancer eller analog eller metabolitt derav for behandling eller forebygging av en immuninflammatorisk forstyrrelse.
NO20080113A 2005-06-17 2008-01-08 Kombinasjonsterapi for behandling av immunoinflammatorisk forstyrrelse NO20080113L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69176605P 2005-06-17 2005-06-17
PCT/US2006/023414 WO2006138518A1 (en) 2005-06-17 2006-06-15 Combination therapy for the treatment of immunoinflammatory disorders

Publications (1)

Publication Number Publication Date
NO20080113L true NO20080113L (no) 2008-02-27

Family

ID=37570780

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20080113A NO20080113L (no) 2005-06-17 2008-01-08 Kombinasjonsterapi for behandling av immunoinflammatorisk forstyrrelse

Country Status (13)

Country Link
US (1) US20070110685A1 (no)
EP (1) EP1895959A4 (no)
JP (1) JP2008543865A (no)
KR (1) KR20080017487A (no)
CN (1) CN101237838A (no)
AR (1) AR054141A1 (no)
AU (1) AU2006259359A1 (no)
BR (1) BRPI0613705A2 (no)
CA (1) CA2612353A1 (no)
IL (1) IL188204A0 (no)
NO (1) NO20080113L (no)
TW (1) TW200711649A (no)
WO (1) WO2006138518A1 (no)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA014372B1 (ru) 2003-01-24 2010-10-29 Стифел Рисерч Оустрэйлиа Пти Лтд. Пена на основе фосфата клиндамицина
WO2008021088A2 (en) * 2006-08-08 2008-02-21 The Regents Of The University Of Californina Salicylanilides enhance oral delivery of therapeutic peptides
US20080306098A1 (en) * 2006-11-06 2008-12-11 Mutz Mitchell W Pharmacokinetics of protease inhibitors and other drugs
US20090054334A1 (en) * 2007-05-23 2009-02-26 Mutz Mitchell W Combinatorial improvement of bifunctional drug properties
EP2178852B9 (en) 2007-08-03 2016-06-22 Romark Laboratories, L.C. Alkylsulfonyl-substituted thiazolide compounds
WO2009055042A1 (en) * 2007-10-24 2009-04-30 Amplyx Pharmaceuticals, Inc. Enhancing the efficacy of anti-infective therapeutics
US9040507B2 (en) * 2008-06-02 2015-05-26 Novelmed Therapeutics, Inc. Method for treating inflammatory conditions
US9623000B2 (en) 2008-07-31 2017-04-18 Dekel Pharmaceuticals Ltd Compositions and methods for treating inflammatory disorders
US20120041019A1 (en) * 2008-12-17 2012-02-16 Mutz Mitchell W Protease inhibitors
KR101147600B1 (ko) * 2009-02-09 2012-05-21 한올바이오파마주식회사 콜레칼시페롤 또는 이의 유도체를 함유하는 피부질환 치료용 외용제 조성물
CN102438590B (zh) 2009-02-25 2013-07-10 施泰福研究澳大利亚有限公司 局部泡沫组合物
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
PE20121118A1 (es) * 2009-05-12 2012-09-05 Romark Lab Lc Compuestos de haloalquil heteroaril benzamida
AP2012006064A0 (en) 2009-06-26 2012-02-29 Romark Lab Lc Compounds and methods for treating influenza.
KR101127928B1 (ko) * 2009-07-23 2012-03-23 대전대학교 산학협력단 섬바디 추출물을 유효성분으로 함유하는 항아토피용 화장료 조성물
US8420054B2 (en) * 2009-09-18 2013-04-16 The Procter & Gamble Company Noninvasive method for measuring histamine from skin as an objective measurement of itch
PT2493471T (pt) * 2009-10-26 2020-01-09 Borody Thomas J Nova terapia de combinação entérica
WO2011075654A1 (en) * 2009-12-18 2011-06-23 Exodos Life Sciences Limited Partnership Methods and compositions for treating inflammation of skin
US10987361B2 (en) 2010-02-08 2021-04-27 Shenzhen Evergreen Therapeutics Co., Ltd. Treating auto-immune and auto-inflammatory diseases
US10993879B2 (en) 2010-02-08 2021-05-04 Shenzhen Evergreen Therapeutics Co., Ltd. Pulmonary delivery of progestogen
EP3689364A1 (en) * 2010-02-08 2020-08-05 Shenzhen Evergreen Therapeutics Co., Ltd. Methods for the use of progestogen as a glucocorticoid sensitizer
US20110206778A1 (en) * 2010-02-25 2011-08-25 Ronald Bourgeois Treatment For Neuropathy, Shingles And Related Disorders
CN102247385A (zh) * 2010-05-19 2011-11-23 天津金耀集团有限公司 含有骨化三醇和布地奈德的吸入制剂及其制备方法
KR20140041505A (ko) 2011-04-29 2014-04-04 셀렉타 바이오사이언시즈, 인크. 조절 b 세포 유도를 위한 관용원성 합성 나노운반체
US8293790B2 (en) * 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
KR101470087B1 (ko) * 2011-11-22 2014-12-10 동국대학교 산학협력단 면역억제제 및 트랜스글루타미나제 ２ 억제제를 포함하는 아토피 피부염의 예방, 치료 또는 개선용 조성물
ES2551427T3 (es) 2012-02-06 2015-11-19 William L. Pridgen Combinación de famciclovir y celecoxib para síndromes somáticos funcionales
US20150017266A1 (en) * 2012-09-05 2015-01-15 Lucille Townsend Compositions and Methods for Relieving Symptoms of Rheumatoid Arthritis and Related Illnesses
ES2924084T3 (es) * 2012-10-11 2022-10-04 Chem Cure Ass Llc Composición tópica para su uso en el tratamiento de la psoriasis
US9717741B2 (en) 2012-10-11 2017-08-01 Anaplasi Pharmaceuticals Llc Method and compositions for treating psoriasis
DK2934520T3 (en) * 2012-12-19 2017-01-23 Polichem Sa USE OF PIDOTIMOD TO TREAT ATOPIC DERMATITIS
HUE052599T2 (hu) * 2013-05-03 2021-05-28 Selecta Biosciences Inc CD4+ szabályozó T-sejtek fokozására szolgáló eljárások és készítmények
EP3068757B1 (en) 2013-11-15 2019-02-27 DS Biopharma Limited Lysine salt of 15-hydroxy-8(z),11(z),13(e)-eicosatrienoic acid
RU2539381C1 (ru) * 2014-04-01 2015-01-20 Общество с ограниченной ответственностью "КОЛЕТЕКС" Способ получения лечебной салфетки
RU2563232C1 (ru) * 2014-04-01 2015-09-20 Общество с ограниченной ответственностью "КОЛЕТЕКС" Способ получения лечебного гидрогеля
ES2784240T3 (es) 2014-06-04 2020-09-23 Ds Biopharma Ltd Composiciones farmacéuticas que comprenden DGLA y uso de las mismas
EA201700051A1 (ru) 2014-08-04 2017-06-30 Фабризио Де Силвестри Применение в одной пилюле, таблетке, капсуле миноциклина, флуконазола и аторвастатина для лечения рассеянного склероза
US20160051570A1 (en) * 2014-08-20 2016-02-25 Ganderland and Associates, Inc. Treatment of rheumatoid arthritis
AU2015311704B2 (en) 2014-09-07 2021-12-09 Selecta Biosciences, Inc. Methods and compositions for attenuating gene editing anti-viral transfer vector immune responses
CN104958754B (zh) * 2015-06-12 2019-04-23 惠州市九惠制药股份有限公司 一种治疗红斑狼疮或银屑病的环孢菌素乳膏及其制备方法和应用
KR102464518B1 (ko) * 2015-12-30 2022-11-07 가톨릭대학교 산학협력단 레스베라트롤과 타크롤리무스의 병용투여에 의한 면역 반응 개선 용도
WO2017154675A1 (ja) * 2016-03-11 2017-09-14 国立大学法人大阪大学 ファブリー病処置剤、外用鎮痛剤、および発汗増進剤
EP3532019B1 (en) 2016-10-31 2023-12-06 Sytheon Limited Skin enhancing compositions and methods
WO2018169811A1 (en) 2017-03-11 2018-09-20 Selecta Biosciences, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
AU2018236168B2 (en) * 2017-03-13 2024-02-29 Beyondspring Pharmaceuticals, Inc. Compositions of plinabulin and use thereof
US20180353539A1 (en) * 2017-06-12 2018-12-13 University Of Southern California Metal complexes as pharmaceuticals for treatment and prevention of cancer and inflammatory diseases
PL239019B1 (pl) * 2017-07-14 2021-10-25 Aflofarm Farm Polska Spolka Z Ograniczona Odpowiedzialnoscia Kompozycja farmaceutyczna w postaci wodnego roztworu, korzystnie syropu, zawierająca pranobeks inozyny oraz glukonianu cynku oraz jej sposób otrzymywania
EP3687541A1 (en) * 2017-09-25 2020-08-05 Obi, Justice, E. Compositions and methods for treatment of bowen's disease and related diseases
EP3727369B1 (en) * 2017-12-20 2025-12-17 Cornell University Anti-fungal agent for use in the treatment of inflammatory bowel disease in a subject with loss-of function mutation in the cx3cr1 gene
GB201810923D0 (en) * 2018-07-03 2018-08-15 Blueberry Therapeutics Ltd Compositions and method of treatment
EP3955916A4 (en) * 2019-04-19 2023-01-25 Buck Institute for Research on Aging 25-HYDROXYCHOLESTEROL (25HC), A CRYAB AGGREGATION INHIBITOR, IS A NEW SENOLYTIC
CN114207440A (zh) 2019-06-04 2022-03-18 西莱克塔生物科技公司 聚乙二醇化尿酸酶的制剂和剂量
EP4034093A1 (en) 2019-12-02 2022-08-03 Sytheon Limited Compositions comprising meroterpenes and linoleic acid derivatives and their use for regulating the endocannabinoid system
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
CN111773193A (zh) * 2020-07-03 2020-10-16 江苏亚虹医药科技有限公司 含硝羟喹啉赖氨酸盐的药物组合物及其制备方法和用途
CN111759840B (zh) * 2020-07-20 2021-05-11 温州市人民医院 一种防治心肌缺血的药物组合物及其制备方法和用途
CN112159826B (zh) * 2020-09-14 2022-05-24 浙江工业大学 一种提高他克莫司产量的方法
US12115186B1 (en) 2023-01-07 2024-10-15 Cyndie Holst Family Trust Topical burn cream
CN116509876B (zh) * 2023-04-24 2024-08-30 大连理工大学 一种负载皮质激素类药聚环糊精-单宁酸纳米粒子及其制备方法和应用
CN117357523A (zh) * 2023-10-25 2024-01-09 澳门大学 利拉萘酯在制备预防和治疗肺纤维化药物中的用途
WO2025106621A1 (en) * 2023-11-14 2025-05-22 Indiana University Research And Technology Corporation Treatment of ulcerative colitis and symptoms thereof
KR102727647B1 (ko) * 2023-11-28 2024-11-08 장병모 칼시뉴린 억제제를 포함하는 피부질환의 예방 또는 치료용 약학적 조성물
CN119679791B (zh) * 2024-11-28 2025-09-23 暨南大学 一种用于治疗溃疡性结肠炎的药物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4512978A (en) * 1980-01-24 1985-04-23 Inwood Louis R Dermatological composition useful in the treatment of psoriasis
US4569935A (en) * 1983-03-17 1986-02-11 University Of Tennessee Research Corp. Topical treatment of psoriasis with imidazole antibiotics
EP1006798A4 (en) * 1996-09-05 2003-03-05 Massachusetts Inst Technology COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS AND NEURODEGENERATIVE DISEASES
US6784156B2 (en) * 2001-03-05 2004-08-31 Enanta Pharmaceuticals, Inc. Cyclosporins for the treatment of respiratory diseases
EP1414466B1 (en) * 2001-07-09 2009-08-19 CombinatoRx, Incorporated Combinations for the treatment of inflammatory disorders
BR0314713A (pt) * 2002-09-24 2005-07-26 Combinatorx Inc Processos e reagentes para o tratamento de doenças e distúrbios associados com nìveis aumentados de citocinas pró-inflamatórias
JP2006517969A (ja) * 2003-02-14 2006-08-03 コンビナトアールエックス インコーポレーティッド 免疫炎症性障害の治療のための組み合わせ療法
EP1781267A4 (en) * 2004-05-17 2009-03-11 Combinatorx Inc METHOD AND REAGENTS FOR THE TREATMENT OF INFAMOUS DISEASES

Also Published As

Publication number Publication date
CN101237838A (zh) 2008-08-06
AU2006259359A1 (en) 2006-12-28
BRPI0613705A2 (pt) 2011-02-01
AR054141A1 (es) 2007-06-06
US20070110685A1 (en) 2007-05-17
KR20080017487A (ko) 2008-02-26
EP1895959A4 (en) 2010-08-11
IL188204A0 (en) 2008-03-20
CA2612353A1 (en) 2006-12-28
TW200711649A (en) 2007-04-01
WO2006138518A8 (en) 2007-04-12
EP1895959A1 (en) 2008-03-12
WO2006138518A1 (en) 2006-12-28
JP2008543865A (ja) 2008-12-04

Similar Documents

Publication Publication Date Title
NO20080113L (no) Kombinasjonsterapi for behandling av immunoinflammatorisk forstyrrelse
NO20053678L (no) Kombinasjonsterapi for behandling av immuninflammatoriske forstyrrelser
NO20062003L (no) Fremgangsmate og forbindelser for behandling av immunoinflammatoriske forstyrrelser
NO20084256L (no) DPP IV inhibitorformuleringer
NO20061239L (no) Fremgangsmater og reagenser for behandling av immunoinflammatoriske forstyrrelser
NO20074044L (no) Meleimidderivater, farmasoytiske preparater og fremgangsmater for behandling av kreft
NO20083877L (no) Sammensetninger og fremgangsmater for behandling av immunoinflammatoriske forstyrrelser
NO20083658L (no) Cyanoisokinolinforbindelser som stabiliserer hypoksi induserbar faktor(HIF)
MX2010003884A (es) Anticuerpo dirigido a la proteina lecitina similar a inmunoglobulina de union a acido sialico-15 relacionado con osteoclastos.
EA201391521A1 (ru) Композиции и способы для ингибирования и/или модулирования эффекторных t-клеток, участвующих в воспалительном нейродегенеративном заболевании
UA107578C2 (uk) Комбінована терапія при лікуванні діабету
EA201270071A1 (ru) Способ лечения пациента, нуждающегося в аспириновой терапии
BRPI0518255A2 (pt) mÉtodos de tratamento ou prevenÇço de uma lesço do sistema nervoso central, para reduzir ou evitar um efeito adverso, e composiÇço farmacÊutica
WO2007048002A3 (en) Camptothecin derivatives as chemoradiosensitizing agents
Wang et al. Simvastatin reverses the downregulation of dopamine D1 and D2 receptor expression in the prefrontal cortex of 6-hydroxydopamine-induced Parkinsonian rats
BRPI0508254A (pt) métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos
Wang et al. Sesamol Mitigates Chronic Iron Overload‐Induced Cognitive Impairment and Systemic Inflammation via IL‐6 and DMT1 Regulation
SG148186A1 (en) Methods and reagents for the treatment of inflammatory disorders
BR112018071991A2 (pt) forma de cristal da dapaglifozina e método para a preparação e uso da mesma
NO20080890L (no) Sammensetninger for a redusere forekomsten av medikamentindusert arytmi
TW200740441A (en) Methods and reagents for the treatment of inflammatory disorders
Tero-Vescan et al. Kynurenine Pathway Metabolites as Mediators of Exercise-Induced Mood Enhancement, Fatigue Resistance, and Neuroprotection
Orlandi et al. Tacrolimus-associated myositis: a case report in a renal transplant patient
BR112012011777A2 (pt) tratamento da exacerbação aguda de asma e redução da probabilidade de hospitalização de pacientes que sofrem dela.
WO2006044665A3 (en) Neuroprotective spirostenol pharmaceutical compositions

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application